Claritev Corp

Análisis de la acción Claritev Corp (CTEV)

$21.540

-1.796 (-8.34%)Al cierre

Loading chart…
Máximo
24.510
Apertura
23.850
Precio medio ponderado por volumen
22.53
Volumen
420.79K
Capitalización
—
Mínimo
21.530
Importe
9.48M
EV/EBITDA, TTM
8.58

Claritev Corp, formerly MultiPlan Corporation, is a healthcare technology, data and insights company. The Company’s services include analytics-based services, data & decision science services, network-based services, payment and revenue integrity, end-to-end surprise billing service, and Claritev payments. The Company uses its analytics-based services to price surprise bills and leverages reimbursement data from millions of claims repriced through these services and accepted by providers to assist in negotiations and calculate offers for arbitration when necessary. It uses its payment integrity services on its network claims. The Company’s payment integrity offers advanced code editing, clinical negotiation, itemized bill review, coordination of benefits, subrogation, data mining, Medicare secondary payer validation, and end stage renal disease validation. It provides solutions for the commercial market, government healthcare plans, and property and casualty healthcare payors.

www.claritev.com

Análisis de IA of Claritev Corp (CTEV)

Comprar

Claritev Corporation (CTEV) appears to be a good buy right now. The current price is $23.50, which is significantly lower than the average analyst price target of $40, indicating a potential upside of over 70%. Additionally, the company has shown a positive trend with a 6.24% increase over the past five days and a narrowed quarterly loss of $59.23 million, down from $62.64 million year-over-year, reflecting improved operational efficiency. However, a key risk is the high debt-to-equity ratio, which stands at 0%, indicating potential financial instability if market conditions worsen.

Métricas de valoración

El PER previsto actual de Claritev Corp (CTEV) es 4.97, frente a su media de 5 años de -0.63.

PER previsto

Sobrevalorado
Media 5A P/E
-0.63
P/E actual
4.97
Sobrevalorada
3.46
Infravalorada
-4.73

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
9.23
EV/EBITDA actual
8.58
Sobrevalorada
9.88
Infravalorada
8.58

Precio/ventas previsto

Valor razonable
Media 5A P/S
0.57
P/S actual
0.37
Sobrevalorada
0.84
Infravalorada
0.31

Escenarios de precio de Alphio AI para CTEV

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%CTEV

$27.94

Precio del escenario

B

Base

Base · 50%CTEV

$26.34

Precio del escenario

B

Bajista

Bajista · 25%CTEV

$21.83

Precio del escenario

Ballenas con CTEV en cartera

A

Ares Management LLC

+ Con en carteraCTEV

-12.41%

Rentabilidad a 3 meses

Cronología de eventos

2026-09-22 (ET)

09:30:00

Claritev Selected to Support World Trade Center Health Program

2026-09-15 (ET)

09:30:00

Claritev Appoints Ben Letham as Director

2026-08-07 (ET)

05:30:00

Claritev Q2 Revenue Reaches $257.48M, Exceeds Expectations

05:30:00

Company Raises FY26 Adjusted EBITDA Outlook to $620M

2026-07-14 (ET)

13:30:00

DOJ Expands Antitrust Investigation into Claritev

Noticias

Preguntas frecuentes sobre CTEV, respondidas por Alphio AI

Claritev Corp, formerly MultiPlan Corporation, is a healthcare technology, data and insights company. The Company’s services include analytics-based services, data & decision science services, network-based services, payment and revenue integrity, end-to-end surprise billing service, and Claritev payments. The Company uses its analytics-based services to price surprise bills and leverages reimbursement data from millions of claims repriced through these services and accepted by providers to assist in negotiations and calculate offers for arbitration when necessary. It uses its payment integrity services on its network claims. The Company’s payment integrity offers advanced code editing, clinical negotiation, itemized bill review, coordination of benefits, subrogation, data mining, Medicare secondary payer validation, and end stage renal disease validation. It provides solutions for the commercial market, government healthcare plans, and property and casualty healthcare payors. It operates in the Industrials sector.

Claritev Corporation (CTEV) appears to be a good buy right now. The current price is $23.50, which is significantly lower than the average analyst price target of $40, indicating a potential upside of over 70%. Additionally, the company has shown a positive trend with a 6.24% increase over the past five days and a narrowed quarterly loss of $59.23 million, down from $62.64 million year-over-year, reflecting improved operational efficiency. However, a key risk is the high debt-to-equity ratio, which stands at 0%, indicating potential financial instability if market conditions worsen.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar